Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …

Overnutrition-related obesity has become a worldwide epidemic, and its prevalence is
expected to steadily rise in the future. It is widely recognized that obesity exerts negative …

Accounting for 16 million new cases and 9 million deaths annually, cancer leaves a great
number of patients helpless. It is a complex disease and still a major challenge for the …

Tumor heterogeneity limits the efficacy and reliability of monospecific radiopharmaceuticals
in prostate cancer diagnosis and therapy. To overcome this limitation and improve lesion …

Targeted alpha‐therapy (TAT) has great potential for treating a broad range of late‐stage
cancers by delivering a focused and lethal radiation dose to tumors. Actinium‐225 (225Ac) …

Purpose: Dendritic cell (DC)-based cancer vaccines is a newly emerging and potent form of
immune therapy. As for any new technology, there are still considerable challenges that …

Targeted α-therapy (TAT) is an emerging powerful tool treating late-stage cancers for which
therapeutic options are limited. At the core of TAT are targeted radiopharmaceuticals, where …

Targeted radionuclide therapy (TRT) is an emerging field and has the potential to become a
major pillar in effective cancer treatment. Several pharmaceuticals are already in routine use …

The nuclear decay characteristics of 225Ac (E α= 5–8 MeV, linear energy transfer (LET)=∼
100 keV/μm, t 1/2= 9.92 days) are well recognized as advantageous for the treatment of …

Abstract Background Actinium-225 (225 Ac, t 1/2= 9.9 d) is a promising candidate
radionuclide for use in targeted alpha therapy (TAT), though the currently limited global …